Target intelligence / Profile preview

Laminin subunit alpha-1 (LAMA1)

Target
LAMA1
Molecular classification
Extracellular matrix protein, Glycoprotein, Laminin family
01

Overview

Laminin subunit alpha-1 (LAMA1) is a major glycoprotein component of the extracellular matrix that assembles with beta-1 and gamma-1 chains to form the heterotrimeric laminin-111 complex. It plays a critical role in basement membrane assembly, cell adhesion, migration, differentiation, and tissue organization, particularly during embryonic development of the brain, kidney, and vascular system. Mutations in the LAMA1 gene are associated with Poretti-Boltshauser syndrome, a rare congenital disorder characterized by cerebellar dysplasia, retinal dystrophy, and intellectual disability. In the therapeutic context, LAMA1 has emerged as a highly promising target for treating LAMA2-related congenital muscular dystrophy (LAMA2-CMD). Because LAMA1 is highly homologous to LAMA2, upregulating its expression can functionally compensate for the lack of LAMA2, restoring basement membrane stability and muscle function. This is being actively pursued through novel epigenetic gene-activation therapies, such as MDL-101, which utilize CRISPR-dCas9 systems to endogenously upregulate LAMA1 in muscle tissue.

Other names
Laminin A chainLaminin-1 subunit alphaLaminin-3 subunit alphaS-laminin subunit alphaS-LAM alphaLAMALAM1PTBHS
02

Mechanism of action

Epigenetic gene activation (upregulation of endogenous LAMA1 expression using CRISPR-dCas9-based transcriptional activators to compensate for LAMA2 deficiency)

03

Biological functions

Cell adhesionCell migrationCell differentiationBasement membrane assemblyTissue developmentNeuron projection developmentAxon guidanceEpithelium branching morphogenesis
04

Disease associations

Congenital muscular dystrophyPoretti-Boltshauser syndromeCancerCerebellar dysplasiaRetinal dystrophyMyopia
05

Safety considerations

AAV vector immunogenicity (pre-existing neutralizing antibodies to AAV9)Off-target epigenetic editingImmune response to dCas9 or other bacterial componentsTissue-specific expression control (risk of ectopic expression outside skeletal muscle)
06

Interacting drugs

07

Biomarkers

LAMA1 expression levelLAMA2 mutation statusAAV9 antibody seronegativity

Beyond the preview

Go deeper on Laminin subunit alpha-1 (LAMA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laminin subunit alpha-1 (LAMA1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call